Lunai Bioworks Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
2Q5
- Investments
-
5
- Share Price
-
$9.72
- (As of Friday Closing)
Lunai Bioworks General Information
Description
Lunai Bioworks Inc is an AI-driven biotechnology company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or lifelong cancer remission in some of the deadliest cancers. The Group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. Its reportable segments are BioSymetrics, which derives the maximum revenue, and RENB. Geographically, the Group operates in the United States and Canada.
Contact Information
Website
www.lunaibioworks.comCorporate Office
- Century City Medical Plaza, 2080 Century City East
- Suite 906
- Los Angeles, CA 90067
- United States
Corporate Office
- Century City Medical Plaza, 2080 Century City East
- Suite 906
- Los Angeles, CA 90067
- United States
Lunai Bioworks Timeline
Lunai Bioworks Stock Performance
As of 22-May-2026, Lunai Bioworks’s stock price is $9.72.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.72 | $9.82 | $9.41 - $30.58 | 4.53M | -$61.39 |
Lunai Bioworks Financials Summary
As of 30-Jun-2026, Lunai Bioworks has a trailing 12-month revenue of $52K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 55,573 | 277,561 | ||
| Revenue | 52 | 52 | 0 | 0 |
| EBITDA | (3,254) | (3,254) | (177,269) | (85,869) |
| Net Income | (3,562) | (3,562) | (178,007) | (88,426) |
| Total Assets | 9,942 | 9,942 | 8,231 | 163,129 |
| Total Debt | 1,338 | 1,338 | 10,173 | 3,787 |
Lunai Bioworks Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lunai Bioworks Patents
Lunai Bioworks Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020294700-A1 | Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity | Inactive | 17-Jun-2019 | ||
| WO-2020257309-A1 | Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity | Inactive | 17-Jun-2019 | ||
| AU-2019306504-A1 | Methods and compositions using recombinant dendritic cells for cancer therapy | Inactive | 15-Jul-2018 | ||
| WO-2020018413-A1 | Methods and compositions using recombinant dendritic cells for cancer therapy | Inactive | 15-Jul-2018 | A61P35/00 |
Lunai Bioworks Signals
Lunai Bioworks Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lunai Bioworks Acquisitions (5)
Lunai Bioworks’s most recent deal was a Merger/Acquisition with Neurobridge IP Holdings for . The deal was made on 01-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neurobridge IP Holdings | 01-May-2026 | Merger/Acquisition | Other Commercial Products | ||
| BioSymetrics | 08-Apr-2025 | Merger/Acquisition | Decision/Risk Analysis | ||
| Renovaro Cube | 13-Feb-2024 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Cyclomics | 01-Feb-2024 | Merger/Acquisition | Biotechnology | ||
| DanDrit | 16-Feb-2018 | Merger/Acquisition | Drug Discovery |
Lunai Bioworks ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.83 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Lunai Bioworks Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cyclomics | Amsterdam, Netherlands | 2017 | |
| BioSymetrics | New York, NY | 2017 |
Lunai Bioworks FAQs
-
When was Lunai Bioworks founded?
Lunai Bioworks was founded in 2011.
-
Where is Lunai Bioworks headquartered?
Lunai Bioworks is headquartered in Los Angeles, CA.
-
What is the size of Lunai Bioworks?
Lunai Bioworks has 12 total employees.
-
What industry is Lunai Bioworks in?
Lunai Bioworks’s primary industry is Discovery Tools (Healthcare).
-
Is Lunai Bioworks a private or public company?
Lunai Bioworks is a Public company.
-
What is Lunai Bioworks’s stock symbol?
The ticker symbol for Lunai Bioworks is 2Q5.
-
What is the current stock price of Lunai Bioworks?
As of 22-May-2026 the stock price of Lunai Bioworks is $9.72.
-
What is Lunai Bioworks’s current revenue?
The trailing twelve month revenue for Lunai Bioworks is $52K.
-
What is Lunai Bioworks’s annual earnings per share (EPS)?
Lunai Bioworks’s EPS for 12 months was -$61.39.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process